UK firm GSK to pay $2.2bn over Zantac cancer claims
The company said in a statement to investors, external that the settlements “remove significant financial uncertainty, risk and distraction associated with protracted litigation.” Zantac was first approved for sale in the US in 1983. Within five years it was the world’s best-selling drug, with annual sales topping $1bn. In 2020, US regulators pulled Zantac off […]